XKRX
102460
Market cap140mUSD
Oct 08, Last price
10,280.00KRW
1D
0.39%
1Q
2.09%
Jan 2017
-53.16%
IPO
-2.63%
Name
Reyon Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
1.29
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.77%
Rev. gr., 5y
2.33%
Revenues
145.93b
-1.60%
Net income
-29.83b
L
CFO
1.23b
P
Dividend
Dec 27, 2024177 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating both domestically in South Korea and across international markets, REYON Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products and active pharmaceutical ingredients (APIs). The company's diverse range of offerings addresses various therapeutic areas, including adrenal corticosteroids; angiotensin II receptor antagonists; anticholinergics; antiemetics; antihypertensives; anti-inflammatory enzymes; lipid-lowering, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer treatments; antispasmodics; benign prostatic hypertrophy therapies; cough and cold remedies; cardiac stimulants; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis medications; local anesthetics; migraine drugs; a variety of cardiovascular system drugs; medications for neuromuscular disorders; nootropics and neurotonics; non-steroidal anti-inflammatory drugs (NSAIDs); respiratory stimulants; skeletal muscle relaxants; and vasodilators. Established in 1955, REYON Pharmaceutical Co., Ltd. maintains its corporate headquarters in Seoul, South Korea.
Key people
Sun Ok Jung
Chairman, Co-Chief Executive Officer · since 2021
Jong Hyeon Park
Senior Vice President · since 2021
Ju Won Cho
Vice President
Seok Jong Choi
Managing Director
Yeong Min Kim
Managing Director
Jin Yong Song
Managing Director
Byeong Ju Lee
Assistant Managing Director
Sun Ah Lee
Assistant Managing Director
Aeng Ran Park
Assistant Managing Director
Jeong Taek Park
Assistant Managing Director
Jeong Seop Shim
Assistant Managing Director
Yong Hwan Yoo
President, Co-Chief Executive Officer, Director · since 2021
Yeong Jun Cho
Non-Executive Independent Director
Taek Gi Hong
Non-Executive Independent Director
Seong Jun Yoon
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||